Document is current
Any future updates will be listed below
-
Authors
Huang, Jiwei https://orcid.org/0000-0002-1463-670X
Wang, Yueming
Xu, Fan
Wang, Zaoyu
Wu, Guangyu
Kong, Wen
Cheoklong, NG
Tricard, Thibault
Wu, Xiaorong
Zhai, Wei
Zhang, Wei
Zhang, Jiyang
Zhang, Ding
Chen, Shuyin
Lian, Yuqing
Chen, Yonghui
Zhang, Jin
Huang, Yiran
Xue, Wei
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04118855 at ClinicalTrials.govnct04394975 at ClinicalTrials.govDocuments that mention this clinical trial
Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial
https://doi.org/10.1136/jitc-2023-008475
nct04118855 at ClinicalTrials.govDocuments that mention this clinical trial
Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial
https://doi.org/10.1136/jitc-2023-008475
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
https://doi.org/10.1136/jitc-2021-004036
Documents that mention this clinical trial
Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial
https://doi.org/10.1136/jitc-2023-008475
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82227801，82102748)
Incubating Program for Clinical Research and Innovation of Renji Hospital (PYIII20-07)
Shanghai Science and Technology Commission Research Project (21ZR1438900)
Basic Oncology Research Program from Bethune Charitable Foundation (BCF-NH-ZL-20201119-024)
Shanghai Health Commission Research Project (202340077)
Wu Jieping Medical Foundation (320.6750.2022-19-92)
- License Information
